Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer

PURPOSE: For postmenopausal patients with hormone receptor-positive early breast cancer, the optimal subgroup and duration of extended endocrine therapy is not clear yet. The aim of this study using the IDEAL patient cohort was to identify a subgroup for which longer (5 years) extended therapy is be...

Descripción completa

Detalles Bibliográficos
Autores principales: Blok, Erik J., Kroep, Judith R., Meershoek-Klein Kranenbarg, Elma, Duijm-de Carpentier, Marjolijn, Putter, Hein, Liefers, Gerrit-Jan, Nortier, Johan W. R., Rutgers, Emiel J. Th., Seynaeve, Caroline M., van de Velde, Cornelis J. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838141/
https://www.ncbi.nlm.nih.gov/pubmed/29230665
http://dx.doi.org/10.1007/s10549-017-4601-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838141/
https://www.ncbi.nlm.nih.gov/pubmed/29230665
http://dx.doi.org/10.1007/s10549-017-4601-1

Ejemplares similares